Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00233506 · ClinicalTrials.gov registry record · Phase 1
A Dose Finding Study of CpG in Patients With Chronic Lymphocytic Leukemia Who Have Been Previously Treated
A Phase 1 study, sponsored by University of Iowa.
- Completed
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
NCT00233506 is a Phase 1 study that has completed, run by University of Iowa. The registered enrollment target is 41 participants.
The verdict
NCT00233506, a Phase 1 study, has completed, sponsored by University of Iowa.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
Study Summary
* CpG has the potential to stimulate the immune system * this study will evaluate the safety of CpG given sub-q or IV * purpose is to measure biological changes in CLL cells after receiving CpG
Interventions
- DRUG CpG 7909
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2004-07 |
| Est. Completion | 2011-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00233506
The ClinicalTrials.gov registry entry for NCT00233506 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Iowa, which has 228 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CpG 7909 is the first listed.
NCT00233506 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00233506 about?
NCT00233506 is a clinical study titled "A Dose Finding Study of CpG in Patients With Chronic Lymphocytic Leukemia Who Have Been Previously Treated". * CpG has the potential to stimulate the immune system * this study will evaluate the safety of CpG given sub-q or IV * purpose is to measure biological changes in CLL cells after receiving CpG
What is the current status of trial NCT00233506?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2004-07. Estimated completion is 2011-06.
What interventions are being tested in trial NCT00233506?
The interventions under investigation include: CpG 7909 (DRUG).
Who is sponsoring clinical trial NCT00233506?
This trial is sponsored by University of Iowa, which has 228 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.